Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab

References

• OgurtsovaKda Rocha FernandesJDHuangYIDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040Diabetes Res Clin Pract2017128405028437734
   PubMed Web of Science ®Google Scholar
• CheungNMitchellPWongTYDiabetic retinopathyLancet2010376973512413620580421
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSEVisual impairment in diabetesOphthalmology198491119
   PubMed Web of Science ®Google Scholar
• FogliSMogaveroSEganCGDel ReMDanesiRPathophysiology and pharmacological targets of VEGF in diabetic macular edemaPharmacol Res201610314915726607863
   PubMed Web of Science ®Google Scholar
• Romero-ArocaPBaget-BernaldizMPareja-RiosALopez-GalvezMNavarro-GilRVergesRDiabetic macular edema pathophysiology: vasogenic versus inflammatoryJ Diabetes Res20162016215627327761468
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edemaEarly Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research groupArch Ophthalmol198510312179618062866759
   PubMedGoogle Scholar
• CiullaTAHarrisAMcIntyreNJonescu-CuypersCTreatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implantExpert Opin Pharmacother201415795395924661081
   PubMed Web of Science ®Google Scholar
• KastelanSTomicMGverovic AntunicaASalopek RabaticJLjubicSInflammation and pharmacological treatment in diabetic retinopathyMediators Inflamm2013201321313024288441
   PubMed Web of Science ®Google Scholar
• BrownDMSchmidt-ErfurthUDoDVIntravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studiesOphthalmology2015122102044205226198808
   PubMed Web of Science ®Google Scholar
• NguyenQDBrownDMMarcusDMRISE and RIDE Research GroupRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology2012119478980122330964
   PubMed Web of Science ®Google Scholar
• RahimyEShahlaeeAKhanMAConversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edemaAm J Ophthalmol2016164118127.e226748058
   PubMed Web of Science ®Google Scholar
• RajendramRFraser-BellSKainesAA 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3Arch Ophthalmol2012130897297922491395
   PubMed Web of Science ®Google Scholar
• KorobelnikJFDoDVSchmidt-ErfurthUIntravitreal aflibercept for diabetic macular edemaOphthalmology2014121112247225425012934
   PubMed Web of Science ®Google Scholar
• WellsJAGlassmanARAyalaARAflibercept, bevacizumab, or ranibizumab for diabetic macular edemaN Engl J Med2015372131193120325692915
   PubMed Web of Science ®Google Scholar
• WellsJAGlassmanARAyalaARDiabetic Retinopathy Clinical Research NetworkAflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trialOphthalmology201612361351135926935357
   PubMed Web of Science ®Google Scholar
• BahramiBHongTZhuMSchlubTEChangASwitching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edemaGraefes Arch Clin Exp Ophthalmol201725561133114028238195
   PubMed Web of Science ®Google Scholar
• LimLSNgWYMathurRConversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumabClin Ophthalmol201591715171826396494
   PubMed Web of Science ®Google Scholar
• MiraFPauloMHenriquesFFigueiraJSwitch to aflibercept in diabetic macular edema patients unresponsive to previous anti-VEGF therapyJ Ophthalmol20172017563263428348885
   PubMed Web of Science ®Google Scholar
• ShahCPHeierJSAflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thicknessOphthalmic Surg Lasers Imaging Retina201647983683927631479
   PubMed Web of Science ®Google Scholar
• WoodEHKarthPAMoshfeghiDMLengTShort-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumabOphthalmic Surg Lasers Imaging Retina201546995095426469235
   PubMed Web of Science ®Google Scholar
• OwsleyCContrast sensitivityOphthalmol Clin North Am200316217117712809156
   PubMedGoogle Scholar
• OuWCBrownDMPayneJFWykoffCCRelationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseasesAm J Ophthalmol201718081728549848
   PubMed Web of Science ®Google Scholar
• ThayaparanKCrosslandMDRubinGSClinical assessment of two new contrast sensitivity chartsBr J Ophthalmol200791674975217166891
   PubMed Web of Science ®Google Scholar
• ArendORemkyAEvansDStuberRHarrisAContrast sensitivity loss is coupled with capillary dropout in patients with diabetesInvest Ophthalmol Vis Sci1997389181918249286271
   PubMed Web of Science ®Google Scholar
• KhoslaPKTalwarDTewariHKContrast sensitivity changes in background diabetic retinopathyCan J Ophthalmol19912617112013027
   PubMed Web of Science ®Google Scholar
• HyvarinenLLaurinenPRovamoJContrast sensitivity in evaluation of visual impairment due to diabetesActa Ophthalmol (Copenh)1983611941016858649
   PubMed Web of Science ®Google Scholar
• KatzGLevkovitch-VerbinHTreisterGBelkinMIlanyJPolatUMesopic foveal contrast sensitivity is impaired in diabetic patients without retinopathyGraefes Arch Clin Exp Ophthalmol2010248121699170320499079
   PubMed Web of Science ®Google Scholar
• SafiSRahimiARaeesiAContrast sensitivity to spatial gratings in moderate and dim light conditions in patients with diabetes in the absence of diabetic retinopathyBMJ Open Diabetes Res Care201751e000408
   Web of Science ®Google Scholar
• DossoAABonvinERMorelYGolayAAssalJPLeuenbergerPMRisk factors associated with contrast sensitivity loss in diabetic patientsGraefes Arch Clin Exp Ophthalmol199623453003058740250
   PubMed Web of Science ®Google Scholar
• PelliDGRobsonJGWilkinsAJThe design of a new letter chart for measuring contrast sensitivityClin Vis Sci198823187199
   Google Scholar
• HaymesSARobertsKFCruessAFThe letter contrast sensitivity test: clinical evaluation of a new designInvest Ophthalmol Vis Sci20064762739274516723494
   PubMed Web of Science ®Google Scholar
• R Core TeamR: A language and environment for statistical computing Available from: https://www.r-project.org/Accessed December 20, 2017
   Google Scholar
• BinderSLoss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?Br J Ophthalmol20129611222157632
   PubMed Web of Science ®Google Scholar
• HanhartJChowersIEvaluation of the response to ranibizumab therapy following bevacizumab treatment failure in eyes with diabetic macular edemaCase Rep Ophthalmol201561445025802504
   PubMedGoogle Scholar
• SarwarSBakbakBSadiqMAFusion Proteins: Aflibercept (VEGF Trap-Eye)Dev Ophthalmol20165528229426501481
   PubMedGoogle Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• De FalcoSThe discovery of placenta growth factor and its biological activityExp Mol Med20124411922228176
   PubMed Web of Science ®Google Scholar
• YancopoulosGDDavisSGaleNWRudgeJSWiegandSJHolashJVascular-specific growth factors and blood vessel formationNature2000407680124224811001067
   PubMed Web of Science ®Google Scholar
• BonninSTadayoniRErginayAMassinPDupasBCorrelation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edemaInvest Ophthalmol Vis Sci201556297898225574055
   PubMed Web of Science ®Google Scholar
• NixonDRFlinnNAEvaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumabClin Ophthalmol20171171572128458510
   PubMed Web of Science ®Google Scholar
• OwsleyCSloaneMEContrast sensitivity, acuity, and the perception of ‘real-world’ targetsBr J Ophthalmol198771107917963676151
   PubMed Web of Science ®Google Scholar
• ZhangJLiuRKuangHYGaoXYLiuHLProtective treatments and their target retinal ganglion cells in diabetic retinopathyBrain Res Bull2017132536028529157
   PubMed Web of Science ®Google Scholar
• LeeBBSunHContrast sensitivity and retinal ganglion cell responses in the primatePsychol Neurosci2011411118
   Google Scholar
• RubinGSBandeen-RocheKHuangGHThe association of multiple visual impairments with self-reported visual disability: SEE projectInvest Ophthalmol Vis Sci2001421647211133849
   PubMed Web of Science ®Google Scholar